Cancer – AALL1131: Phase 2 Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia including a Stratum Evaluating Dasatinib in Patients with Ph-like Tyrosine Kinase Inhibitor Sensitive Mutations
Condition or Therapy:
B acute lymphoblastic leukemia, CNS leukemia, Ph-like ALL, testicular leukemia
Cancer and blood disorders
Study Number: AALL1131
What is the goal of this study?
Researchers want to understand how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are 1 to 30 years old, and
- Have been newly diagnosed with B lymphoblastic leukemia.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.